DNA methylation is an epigenetic mechanism regulating patterns of gene expression. Our goal was to see if the assessment of DNA methylation might be a useful tool, when used in conjunction with initial, basic in vitro tests, to provide a more informative preliminary appraisal of the toxic potential of chemicals to prioritize them for further evaluation. We sought to give better indications of a compound's toxic potential and its possible mechanism of action at an earlier time and, thereby, contribute to a rational approach of an overall reduction in testing by making improved early decisions. Global and GC-rich patterns of DNA methylation were evaluated along with more traditional cytolethality measurements, e.g., cytolethality and genotoxicity assessments, on rat hepatoma (H4IIE) cells. The relative toxic potential of model compounds camptothecin, 5-fluorouracil, rotenone, and staurosporine was estimated by employing DNA methylation assessments combined with our cytolethality data plus genotoxicity information gleaned from the literature. The overall contribution of the methylation assessment was threefold; it (1) strengthened a ranking based on genotoxicity; (2) provided an indication that a compound might be more potentially problematic than what cytolethality and genotoxicity assessments alone would indicate; and (3) suggested that compounds, particularly nongenotoxins, that are more potent regarding their ability to alter methylation, especially at noncytolethal concentrations, may be more potentially toxic. Altered methylation per se is not proof of toxicity; this needs to be viewed as a component of an evaluation.
There is an increasing need for more informative preliminary tests to predict the toxic potential of chemicals to prioritize them for further evaluation. This is pertinent for the screening of environmental compounds as well as for the development of medicines and consumer products. For practical purposes, when faced with large numbers of small amounts of compounds, initial evaluations are based on the results of in vitro studies. Clearly, the initial assessments should be predictive of in vivo toxic effects and amenable to dose-(concentration-) response analysis. In light of the recent change in the paradigm of drug discovery leading to the development of very limited quantities of numerous potential lead compounds using combinatorial chemistry, the need for enhanced in vitro approaches for basic, initial assessment of toxicity is particularly acute in the pharmaceutical industry (Furka, 2002) . In this context, it is important to note that a high percentage of potential new medicines currently fail due to toxicity, often during preclinical or clinical trials, resulting in a significant waste of time and resources (Cockerell et al., 2002) .
Typically, initial assessments of toxicity include measurements of cytolethality and genotoxicity (including mutagenicity). Knowledge concerning the mutagenic potential of a compound is an important component of a basic, initial safety assessment (Ames et al., 1979; Rueff et al., 1996) . However, different mutagenicity assays performed on the same compound can produce markedly disparate results (Choi et al., 1996) . Structure-activity relationships often provide a basis for selection of potential drug candidates in the pharmaceutical industry, and this approach has also been used to try to identify compounds acting at sites known to elicit a toxic response (Woo et al., 1995) . Toxicogenomics holds out the potential to develop into a useful screening tool for identification of the toxic potential of chemicals (Tennant, 2002) . However, a substantial effort, including data analysis, is necessary to evaluate this approach more thoroughly before it can be employed on a routine basis.
We propose that DNA methylation analysis might be a useful tool when used in conjunction with initial, basic in vitro tests, e.g., cytolethality and genotoxicity assessments. This can provide increased knowledge of a chemical's toxic potential and contribute to an enhanced ability to prioritize compounds for further evaluation. Methylation of DNA cytosine residues is an epigenetic mechanism that regulates gene expression as well as tissue-specific, developmental, immunological, and neurological processes (Robertson and Jones, 2000) . Both hypo-and hypermethylation may lead to deleterious effects. In general, increases in methylation at promoter regions lead to transcriptional silencing by directly hindering the binding of transcription factors or by recruiting proteins that bind methylated cytosines, e.g., chromatin deacetylase (Attwood et al., 2002) . Conversely, hypomethylation may lead to the increased expression of certain oncogenes and/or the loss of genomic stability by the expression of transposable elements that are normally silenced by methylation (Carnell and Goodman, 2003; Counts and Goodman, 1995) . Alterations to normal patterns of methylation have been shown to play a role in cancer (Counts and Goodman, 1995) as well as in developmental, neurological, and immunological disorders (reviewed in Watson and Goodman, 2002a) . Thus, altered methylation can lead to aberrant transcription of genes and, therefore, might form a basis for a variety of toxic outcomes. However, there is a possible positive side in that compounds that are found to affect methylation might be useful in cancer therapy; a currently employed anticancer drug, azacytosine, acts by decreasing DNA methylation.
We performed DNA methylation analysis in conjunction with more traditional cytolethality assessments on rat hepatoma (H4IIE) cells treated with the known demethylating agent azacytidine and the model compounds camptothecin, 5-fluorouracil (5-FU), rotenone, and staurosporine. Our goal was to see if assessments of DNA methylation might assist in improving basic, initial toxicological screens.
In our view, the appropriate initial approach should be a general one, involving an evaluation of global methylation status and an assessment of methylation in GC-rich regions of the genome, rather than an attempt at gene-specific evaluations. We do not want to simply add new tests. On the contrary, our aim was to determine if the assessment of DNA methylation, with an emphasis on dose-response relationships, could provide a useful added dimension to basic, initial toxicity assessment of a compound's toxic potential and an earlier indication of its possible mechanism of action. This could aid in selecting and prioritizing those compounds that should be considered for further evaluation and contribute to an overall reduction in testing by making improved early decisions.
MATERIALS AND METHODS
Cell culture and DNA purification. H4IIE rat hepatoma cells (between passages 7-9) were grown in 96-and 6-well plates for in vitro toxicity analysis and for methylation analysis, respectively. We have conducted experiments to ascertain that results from these in vitro toxicity assessments do not vary between 96-and 6-well plates (data not shown). Cells to be used for methylation analysis were dosed with concentrations of compounds deemed to be cytolethal and noncytolethal based on a battery of in vitro cytolethality assessments. After a 72 h incubation, cells were washed twice with PBS, trypsinized, centrifuged, and frozen at -80°C until use. DNA was extracted using Trizol reagent (Sigma-Aldrich, St. Louis, MO) and stored at 4°C until use.
Proof of principle compound: 5-aza-2deoxycytidine. Our initial studies focused on our proof-of-principle compound 5-aza-2Јdeoxycytidine (dAzaC, purchased from Sigma-Aldrich), a cytosine analog known to cause demethylation by incorporating into DNA and irreversibly binding DNA methyltransferase, thus inhibiting methylation of newly replicated DNA (Lu and Randerath, 1984) .
Model compounds.
Following the initial studies with dAzaC, four model compounds with varying modes of action and different toxic effects were selected. None of these compounds were known to have any effect on DNA methylation. Camptothecin is an S-phase-specific anticancer agent that inhibits the activity of DNA topoisomerase I, leading to replication fork arrest as well as single-and double-strand DNA breaks (Morris and Geller, 1996) . 5-FU is a pyrimidine analog that is metabolized to 5-fluorodeoxyrudine monophosphate, a compound that competes with deoxyuridine monophosplate for thymidylate synthetase. Normally, thymidylate synthetase catalyzes the conversion of deoxyuridine monophosphate to thymidine monophosphate, a precursor of thymidine triphosphate and a necessary component of DNA (Parker and Cheng, 1990) . Thus, the overall effect of 5-FU is to inhibit replication. Rotenone inhibits complex I of the mitochondrial oxidative phosphorylation chain, stopping the supply of electrons to quinol cytochrome c oxidoreductase. This decreases adenosine triphosphate (ATP) production and the release of cytochrome c from the mitochondria; the increased permeability of the mitochondrial membrane leads to caspase-mediated apoptosis (Pei et al., 2003) . Staurosporine is a nonspecific inhibitor of protein kinases that promotes apoptosis through both caspase-dependent and -independent mechanisms (Belmokhtar et al., 2001) . Staurosporine also inhibits the catalytic activity of topoisomerase II by blocking the transfer of phosphodiester bonds from DNA to the active tyrosine site (Lassota et al., 1996) . All compounds described were purchased from Sigma-Aldrich.
In vitro toxicity assessments. In vitro toxicity assessments for each compound included measurements of ATP, cell number, glutathione-S-transferase (GST), and 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) as part of the Tox Cluster battery of assays described elsewhere (McKim et al., 2001) .
ATP assay. ATP serves as the principal immediate donor of free energy and is present in all metabolically active cells (Crouch et al., 1993) . Levels of ATP decline rapidly when cells are injured, and this can be easily measured using an ATP bioluminescence assay in which a luciferin ATP substrate was added and interacted with ATP and oxygen to form oxyluciferin, AMP, PP i , CO 2 , and light (Crouch et al., 1993) . The ATPLite-M bioluminescence assay kit (PerkinElmer Life and Analytical Sciences, Inc., Boston, MA) was used to measure the amount of ATP in the H4IIE cells. The amount of ATP is extrapolated from the amount of light emitted as measured by a spectrophotometer (Packard, Palo Alto, CA). Results are expressed as percentages of control values. Cellular proliferation assay. Measurements of cellular proliferation provide a general measure of toxicity. Cell number was assessed using the CyQUANT cell proliferation assay kit from Molecular Probes (Eugene, OR), a highly sensitive, fluorescence-based microplate assay for determining the number of cultured cells (Jones et al., 2001) . Cells were rinsed with PBS to remove dead cells no longer adhering to the plate, lysed, and the DNA was stained using the CyQUANT fluorescent dye. Fluorescence was measured using a Packard Spectracount fluorescence reader. Using a standard curve generated from fluorescence readings of known amounts of H4IIE cells, the cell numbers in our samples were extrapolated.
GST assay. GST leakage is linked to a loss of membrane integrity and necrosis in hepatocytes, and, thus, the amount of GST is related to cell viability (Giannini et al., 2000) . To measure GST release into the serum, we used the rat ␣ GST enzyme immunoassay (Biotrin International, Dublin, Ireland) . After 72 h, serum from the cells was removed, diluted 1:4 with media, and 100 l/well of the diluted serum were placed into 96-well plates coated with IgG antibody. The cells were incubated for 1 h at room temperature using a rotary mixer. Plates were then washed six times using the Biotrin wash buffer. After removing all the fluid from the plate, 100 l/well of the Biotrin conjugate were added. This conjugate binds to the IgG-bound GST. Plates were incubated with the conjugate for 1 h at room temperature using a rotary mixer and then washed six times using Biotrin wash buffer. After removing all the fluid from the plate, 179 DNA METHYLATION ASSESSMENT AND TOXICITY 100 l of Biotrin TMB substrate were added to each well. The plates were incubated for 15 min at room temperature using a rotary mixer. Following incubation, 50 l stop solution were added to each well and plates were read using a Packard Spectracount spectrophotometer. The percentages of damaged GST-releasing cells and nondamaged cells (not releasing GST above basal values) were determined using a standard curve generated from standards containing known percentages of control and 50 M digitonin-treated cells. Digitonin damages cells and elicits GST release. GST results are presented as the percentages of control cells not releasing GST above basal values.
MTT assay. MTT analysis provides a general measurement of mitochondrial dehydrogenase activity and cell viability (Rodriguez and Acosta, 1997) . The MTT assay is based on the reduction of the soluble yellow MTT tetrazolium salt to a blue MTT formazan product by mitochondrial dehydrogenases (Mosman, 1983) . Each well of H4IIE cells within 96-well plates was incubated with 100 l of a 0.5 mg/ml MTT solution for 3 h. Following the MTT incubation, the media were removed by aspiration and 200 l isopropanol were added to each well to dissolve and solubilize the intracellular MTT formazan product. After a 20 min incubation with isopropanol (with shaking) in the dark, the optical density of each well was assessed at 570 and 850 nm using a Packard Spectracount spectrophotometer. Results are expressed as percentages of control values. The MTT assay was purchased from Sigma-Aldrich.
Rationale by which cytolethal and noncytolethal concentrations of compounds were selected. Based on dose-response analysis, the threshold concentration was estimated to be the first concentration below which there was no statistically significant change compared to measurements in untreated control cells and above which there was a significant change in at least two of the parameters. A concentration equal to 10 -25% of this value was used as the noncytolethal concentration. The cytolethal concentration was selected as the first concentration at which the percentages of control values for at least two of the assays were between 25 and 40%. Thus, noncytolethal and cytolethal concentrations were chosen in a uniform manner for each model compound. Also, these parameters were used to select noncytolethal concentrations of dAzaC.
Global DNA methylation analysis: SssI methylase assay. SssI methylase uses S-adenosyl methionine (SAM) as a methyl group donor to methylate the 5Ј position of cytosine at unmethylated CpG sites in DNA. Thus, the level of global DNA methylation can be determined by the amount of tritiated methyl groups from [ 3 H-CH 3 ] S-adenosyl-L-methionine incorporated into DNA, since there is an inverse relationship between incorporation of radioactivity and the original degree of methylation (Balaghi and Wagner, 1993) . DNA (1 mg) was incubated with 2 Ci [ 3 H-CH 3 ] S-adenosyl-L-methionine (New England Nuclear, Boston, MA) and 3 units of SssI methylase (New England Biolabs, Beverly, MA) for 1 h at 30°C. Results are presented as counts per minute per microgram (cpm/g) DNA. Five replicates were performed per sample. Graphical presentation was performed using Excel (Microsoft Corp., Redmond, WA). Statistical analysis was performed with Excel using two-tailed t-tests to compare the average cpm/g DNA measurements of treatment groups and controls. A p value of Ͻ 0.05 was considered statistically significant.
Methylation analysis of GC-rich regions: restriction digests. For each DNA sample, three restriction digests were performed as follows: RsaI alone, RsaI and MspI, and RsaI and HpaII. RsaI is a methylation-insensitive enzyme used to cut the DNA into smaller fragments. Both MspI and HpaII are methylation-sensitive enzymes that cut between cytosine residues at 5Ј-CCGG-3Ј sites. MspI will not cut if the external cytosine is methylated, and HpaII will not cut if the internal cytosine is methylated. Both MspI and HpaII will cut if the site is unmethylated (Mann and Smith, 1977) . All enzymes used were from Roche (Indianapolis, IN). Restriction digests were performed with 1 g DNA and 5.0 units RsaI in Roche buffer L. After a 1 h incubation (with shaking) in a water bath at 37°C, two 2.5-unit aliquots of MspI or HpaII were added, 2 h apart. The total incubation time was 18 h. The enzymes were inactivated by a 10 min incubation at 65°C, and the digests were stored at 4°C until amplified by PCR.
Arbitrarily primed (AP)-[
33 P] PCR. PCR was performed on restriction digests using a single primer (5Ј-AACCCTCACCCTAACCCCGG-3Ј) that arbitrarily binds within GC-rich regions of DNA (Gonzalgo et al., 1997) . Reactions were composed of 5 l of the restriction digest (containing 1 g digested DNA), 0.4 M of each primer, 1.25 units of Taq polymerase (Gibco BRL, Rockville, MD), 1.5 mM MgCl 2 , 60 mM Tris, 15 mM ammonium sulfate, 1.65 Ci ␣-[
33 P]-dATP (New England Nuclear, Boston, MA), and glass-distilled water to volume. Samples were heated for 5 min at 94°C before the addition of dNTPs to minimize the possibility of primer-dimer formation. Cycling conditions included a single denature cycle for 2 min at 94°C, followed by five cycles under the following conditions: 30 s at 94°C, 1 min at 40°C, 1.5 min at 72°C; then, 30 cycles at 94°C for 30 s, 55°C for 15 s, and 72°C for 1 min, a time delay cycle for 5 min at 72°C, and a soak cycle at 4°C. PCR products (5 l of each) were separated on a 6% polyacrylamide sequencing gel at 45 watts for 2 1 ⁄4 -2 1 ⁄2 h. The gel was soaked for 10 min in a fixing solution with 5% acetic acid and 5% methanol, rinsed for 10 min in glassdistilled water, dried, and placed into a cassette with a storage phosphoimage screen to visualize labeled PCR products. Compared with larger DNA fragments on the upper halves of gels, smaller fragments on the lower halves of gels sometimes required a longer exposure to clearly discern bands. Thus, a short exposure of 3 d followed by a longer exposure of 8 d was often performed on a gel. Phosphoimages were analyzed using Quantity One software (Bio-Rad, Hercules, CA).
RESULTS
Firstly, we wanted to determine how the existing in vitro toxicity analysis compared with methylation analysis using dAzaC, a drug known to alter DNA methylation. Studies were performed using H4IIE cells treated with 10 and 100 M dAzaC; both concentrations were found to be noncytolethal based on in vitro toxicity analysis. These concentrations of dAzaC decreased global methylation levels in a dose-dependent manner (Fig. 1) . Furthermore, arbitrarily primed PCR results showed that, in the treated samples, there were five GC-rich regions in which there was a greater amount of methylation at the external cytosines at 5Ј-CCGG-3Ј sites and two 
180
GC-rich regions in which there was a greater amount of methylation at the internal cytosines at 5Ј-CCGG-3Ј sites, compared with untreated controls (Fig. 2) .
Cytolethal and noncytolethal concentrations were chosen for the model compounds based on in vitro toxicity data, as shown in Figure 3 . Global methylation status in cells treated with both cytolethal and noncytolethal concentrations of these compounds is shown in Figure 4 . Global methylation levels of cells treated with both cytolethal and noncytolethal concentrations of camptothecin were not significantly different from the untreated controls. However, treatment with a cytolethal dose of 5-FU and a noncytolethal dose of staurosporine led to statistically significant (p Ͻ 0.05) decreases in the global level of methylation. A cytolethal concentration of staurosporine led to a reduction in global methylation levels, but this was not statistically significant (p ϭ 0.08). Also, at both cytolethal and 181 noncytolethal concentrations, rotenone seemed to increase global levels of DNA methylation, though this was not statistically significant (p ϭ 0.12 and 0.09, respectively).
GC-specific methylation status was assessed for cytolethal doses of all the model compounds (Fig. 5) . A cytolethal concentration of campothecin (Fig. 5A) or rotenone (Fig. 5C ) resulted in no detectable alterations in the GC-rich methylation patterns of H4IIE cells compared with controls. Treatment with a cytolethal concentration of 5-FU (Fig. 5B ) induced hypermethylation at the internal cytosine of the 5Ј-CCGG-3Ј site in six GC-rich regions, hypomethylation at the internal cytosine in three GC-rich regions, and hypomethylation at the external cytosine in two GC-rich regions. Treatment with a cytolethal concentration of staurosporine (Fig. 5D) resulted in hyper-FIG. 3 . In vitro toxicity assessments of (A) camptothecin, (B) 5-FU, (C) rotenone, and (D) staurosporine. In vitro assays included measurements of ATP, cell number, GST, and MTT. Percentages of control values for a range of concentrations are indicated. Thick horizontal bars indicate the 25-40% control range used to select cytolethal concentrations for each compound. The thick vertical line indicates the threshold dose below which at least three parameters do not vary significantly from control values and above which at least two parameters are statistically below the percentages of control values of the preceding concentration. The dotted vertical line indicates the noncytolethal concentration, chosen to be 10 -25% of the threshold. The dashed vertical line indicates the cytolethal concentration. Data were analyzed and cytolethal and noncytolethal concentrations were selected as indicated in a uniform manner for each model compound. Two replicates of the full set of toxicological parameters were performed for each compound and the results were highly reproducible. (E) A summary of threshold, cytolethal, and noncytolethal concentrations chosen for each compound is shown. 182 methylation at the external cytosine of the 5Ј-CCGG-3Ј site in five GC-rich regions. Since treatment with cytolethal concentrations of 5-FU and staurosporine led to alterations in GC-rich methylation, the GC-rich methylation status of cells treated with noncytolethal concentrations of these compounds was assessed (Fig. 6) . The noncytolethal concentration of 5-FU did not lead to any GC-specific methylation alterations (Fig. 6A) , but the noncytolethal concentration of staurosporine led to increases and decreases in methylation at the internal cytosine of the 5Ј-CCGG-3Ј site in five and (Fig. 6B) . A summary of the results of global and GC-rich DNA methylation analysis is presented in Table 1 .
DISCUSSION
Based on the results of our investigation, we believe that the inclusion of an assessment of methylation status, with an emphasis on dose-response relationships, as a component of initial, preliminary toxicity testing can help in the prioritization of compounds at early screening stages and contribute to a better understanding of possible mechanisms underlying toxicity. For instance, if two compounds exhibit similar results from cytotoxicity and genotoxicity assays but one compound affects methylation at low doses and the other does not, this could provide a basis for considering the latter to be less potentially toxic. More effective prioritization is expected to result in an overall decrease in time, cost, and testing.
We performed methylation analysis by examining both global and GC-rich methylation in H4IIE cell DNA. These approaches assess different and, importantly, complementary aspects of genome-wide methylation. A focus on gene-specific methylation would not be appropriate during initial toxicity testing, in part because one would not know which gene(s) to examine and compound-specific changes could be anticipated. Global and GC-rich methylation patterns might be regulated by different methyltransferases and may be affected as a result of the administration of a specific compound. For example, our data show that dAzaC, a demethylating agent that irreversibly binds and, thus, inactivates methyltransferases, decreased global methylation as expected but also increased methylation at GC-rich sites. Other studies have reported that dAzaC treat- 184 ment reduces global levels of methylation while increasing methylation at select regions (Broday et al., 1999; Grassi et al., 2003) . The basis for the latter effect is not known, but this finding indicates that dAzaC might affect methylation at GCrich regions in a manner secondary to its known mode of action and provides an additional example of the importance of examining both global and GC-specific methylation patterns.
In support of this, it should be noted that DNMT1 and DNMT3b methyltransferases have a greater in vivo binding avidity to dAzaC-containing DNA compared with DNMT2 and 3a (Liu et al., 2003) . Perhaps in response to decreasing availability of DNMT1 and 3b, amounts of DNMT2 and 3a are upregulated as a result of azacytidine treatment and the GCrich regions, shown to be hypermethylated as a result of dAzaC treatment, are methylated by these methyltransferases. Even if methylation is affected by a secondary or tertiary mechanism, this finding nonetheless provides more insight into a compound's actions than solely relying on cytotoxicity assessments. Furthermore, mice given phenobarbital exhibited global hypomethylation in liver DNA (Counts et al., 1996) with increased hypermethylation in GC-rich regions (Watson and Goodman, 2002b) . Thus, it is informative to look at both global and GC-specific changes.
There are multiple ways in which DNA methylation may be altered, including perturbing the 1-carbon choline/folate/ methionine metabolic pathway required for the synthesis of SAM, the proximate methyl group donor for DNA (Zeisel and Blusztajn, 1994) . For example, arsenic is methylated by SAM, and administration of arsenic is thought to hypomethylate DNA by decreasing the availability of SAM (Okoji et al., 2002) . Maintenance of normal DNA methylation may be viewed as a basic homeostatic mechanism. Therefore, detec- Note. For each compound, the threshold value was estimated to be the concentration below which there was no statistically significant change in cytolethality compared with untreated control cells and above which there was a significant change in at least two cytolethality parameters. A concentration used that was equal to 10 -25% of the threshold value was employed. The cytolethal concentration used was selected as the lowest concentration at which the percentages of control values for at least two cytolethality parameters were between 25 and 40%.
a The model compounds presented in Table 1 are now indicated by letter to de-emphasize the knowledge of their mechanisms of action and to focus on the use of methylation data to derive an estimated toxic potential ranking.
b A, camptothecin; B, 5-FU; C, rotenone; and D, staurosporine. c Estimated relative potential to elicit a toxic reponse, such that a higher number represents a potentially safer compound and a lower number represents one more likely to be problematic. Note. For each compound, the threshold value was estimated to be the concentration below which there was no statistically significant change in cytolethality compared with untreated control cells and above which there was a significant change in at least two cytolethality parameters. A concentration equal to 10 -25% of the threshold value was used as the noncytolethal concentration. The cytolethal concentration was selected as the first concentration at which the percentages of control values for at least two cytolethality parameters were between 25 and 40%.
b A, camptothecin; B, 5-FU; C, rotenone; and D, staurosporine. c Estimated relative potential to elicit a toxic response, such that a higher number represents a potentially safer compound and a lower number represents one more likely to be problematic.
d These compounds were assigned the same rank because the cytolethal concentrations were nearly equivalent.
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DNA METHYLATION ASSESSMENT AND TOXICITY tion of alterations of this might enhance early basic toxicity screening by providing a broader picture of a compound's potentially toxic effects.
Typically, basic, initial toxicity assessments involve in vitro studies aimed at ascertaining the compound-of-interest's cytolethal and genotoxic effects. To show the potential importance of the evaluation of DNA methylation for compound prioritization, we estimated the relative toxic potentials of the model compounds used in this study by employing DNA methylation assessments combined with the cytolethality data presented plus genotoxicity information gleaned from the literature. For the latter, we searched for data concerning four basic in vitro tests: the Ames test, the sister chromatid exchange, chromosome aberrations, and the mouse lymphoma assay. Our model compounds are indicated by letters (to de-emphasize the fact that we have knowledge of their mechanisms of action) as follows: A represents camptothecin, B represents 5-FU, C represents rotenone, and D represents staurosporine. Using methylation analysis alone, the compounds were ranked according to estimated toxic potentials at cytolethal and noncytolethal concentrations, such that a higher number indicates a safer compound compared to one ranked with a lower number ( Table 2) . At cytolethal concentrations, compounds B and D affected multiple changes in DNA methylation while A and C did not. Thus, B and D would be ranked as more toxic than A and C (Table 2) . However, at noncytolethal concentrations, only compound D affected DNA methylation. We viewed methylation alterations at noncytolethal concentrations as being more significant than changes that occured only at cytolethal concentrations. Therefore, D is ranked more toxic than A, B, and C (Table 2) . Thus, if all four compounds were nongenotoxic, methylation data plus information concerning cytolethality could be very helpful to an initial prioritization of potential toxicity.
Compounds were also ranked based on the concentrations at which a cytolethal effect was obtained (Table 3) . This is a crude method of ranking, likely to be important only if a compound is toxic at very low (pM) concentrations or if there is an extreme range of potencies of the compounds-of-interest. In this case, the cytolethal concentrations of the model compounds are within a 100-fold range. The genotoxicity data are presented in Table 4 . We then used the genotoxicity data with and without the cytolethality data (Table 3) to rank the compounds based on estimated toxic potential. Genotoxicity data alone indicated that, since A and B are genotoxic and C is not, A and B would be more likely to pose a toxic response than C (Table 5 ). Cytolethality data indicated that a lower dose of A Note. For the purposes of this table, the search for genotoxicity data was limited to results of the four common tests presented. These data were obtained from references cited in TOXLINE, National Institutes of Health, and National Toxicology Program databases (http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen? TOXLINE, http://toxnet.nlm.nih.gov/cgi-fin/sis/htmlgen?Multi, and http://ntp-server.niehs.nih.gov, respectively).
b A, camptothecin; B, 5-FU; C, rotenone; and D, staurosporine.
186 was needed to elicit a cytolethal effect than B, thus permitting these two compounds to be separated in ranking (Table 5) . Finally, methylation data at noncytolethal concentrations were combined with genotoxicity and cytolethality data to rank the compounds (Table 6 ). Though compound C was most cytolethal, it ranked least potentially toxic when genotoxicity and methylation data were also considered (Table 6 ). If data were available indicating that compound D was equal to or more genotoxic than A and B, then D would be considered the most potentially toxic of the group (Fig. 6B) . The overall contribution of DNA methylation assessments in this initial, toxic-potential evaluation exercise was threefold: (1) it both supported and strengthened the ranking based on genotoxicity, indicating that compound C was less potentially toxic than compounds A and B in this example; (2) it provided an indication that compound D was more potentially problematic than indicated by cytolethality and genotoxicity assessments; and (3) for nongenotoxic compounds, it showed that those that were more potent with regard to their ability to alter methylation, particularly at noncytolethal concentrations (Table 2), may be more potentially toxic.
It is very important to recognize that an alteration in DNA methylation alone is not necessarily indicative of toxicity; certain changes in methylation might be representative of normal biological processes, and methylation is a reversible mechanism (Ramchandani et al., 1999) . Also, one must consider that human cells are more capable of maintaining normal methylation status compared to rodent cells (reviewed in Goodman and Watson, 2002) . For these reasons, methylation analysis needs to be viewed as a component of an overall toxicity assessment.
This study serves as a promising first step in assessing the utility of methylation analysis in early stages of toxicity testing. A next step should involve in vitro and in vivo doseresponse comparisons linked to histopathology and take reversibility into consideration (e.g., are the in vitro data predictive of in vivo toxicity and is methylation status altered in target organs?). Future experiments should examine the effects of different compounds within particular chemical classes. Currently, gene array approaches to assess methylation status are too cumbersome as far as cost and data analysis issues to be used on a routine, initial basis. Attempts should be made to adapt methylation analysis to high-throughput approaches (e.g., separation of random primed PCR products by capillary electrophoresis rather than the use of polyacrylamide gels). a The model compounds presented in Table 1 are now indicated by letter to de-emphasize the knowledge of their mechanisms of action and to focus on the use of methylation data to derive an estimated toxic potential ranking.
d The ranking of D relative to A and B was not determined because we cannot compare the relative toxic potentials of a compound that elicited changes in methylation (D) with those that elicit positive results in genotoxicity assays (A and B).
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